{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T19:18:15Z","timestamp":1747163895440,"version":"3.40.5"},"reference-count":33,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","canadianjournalofophthalmology.ca","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Canadian Journal of Ophthalmology"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1016\/j.jcjo.2024.06.004","type":"journal-article","created":{"date-parts":[[2024,7,31]],"date-time":"2024-07-31T19:12:34Z","timestamp":1722453154000},"page":"113-119","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Long-term visual outcomes and fluid compartment changes in limited-early versus early response to anti-VEGF treatment for diabetic macular edema"],"prefix":"10.1016","volume":"60","author":[{"given":"Christian","family":"Akotoye","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6197-9476","authenticated-orcid":false,"given":"Scott W.","family":"Perkins","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Neha","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7725-1631","authenticated-orcid":false,"given":"Rishi P.","family":"Singh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jcjo.2024.06.004_bib0001","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1159\/000455277","article-title":"Diabetic macular edema","volume":"58","author":"Bandello","year":"2017","journal-title":"Macular Edema"},{"key":"10.1016\/j.jcjo.2024.06.004_bib0002","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1001\/jamaophthalmol.2014.2854","article-title":"Prevalence of and risk factors for diabetic macular edema in the United States","volume":"132","author":"Varma","year":"2014","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.jcjo.2024.06.004_bib0003","doi-asserted-by":"crossref","first-page":"240","DOI":"10.3109\/08820539909069543","article-title":"Molecular mechanisms of vascular permeability in diabetic retinopathy","volume":"14","author":"Antonetti","year":"1999","journal-title":"Sem Ophthalmol"},{"key":"10.1016\/j.jcjo.2024.06.004_bib0004","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1097\/00006982-199515020-00026","article-title":"Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders","volume":"15","author":"Aiello","year":"1995","journal-title":"Retina"},{"key":"10.1016\/j.jcjo.2024.06.004_bib0005","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.survophthal.2008.10.001","article-title":"Diabetic macular edema: Pathogenesis and treatment","volume":"54","author":"Bhagat","year":"2009","journal-title":"Surv Ophthalmol"},{"key":"10.1016\/j.jcjo.2024.06.004_bib0006","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1097\/IAE.0000000000002110","article-title":"Association between early anatomic response to anti\u2013vascular endothelial growth factor therapy and long-term outcome in diabetic macular edema","volume":"39","author":"Dugel","year":"2019","journal-title":"Retina"},{"key":"10.1016\/j.jcjo.2024.06.004_bib0007","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1136\/bjophthalmol-2020-317416","article-title":"Automated quantification of macular fluid in retinal diseases and their response to anti-VEGF therapy","volume":"106","author":"Michl","year":"2020","journal-title":"Brit J Ophthalmol"},{"key":"10.1016\/j.jcjo.2024.06.004_bib0008","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.ajo.2021.06.030","article-title":"Fluctuations in central subfield thickness associated with worse visual outcomes in patients with diabetic macular edema in clinical trial setting","volume":"232","author":"Starr","year":"2021","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.jcjo.2024.06.004_bib0009","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1590\/S0004-27492012000300007","article-title":"Correlation between central subfield thickness, visual acuity and structural changes in diabetic macular edema","volume":"75","author":"Hannouche","year":"2012","journal-title":"Arq Brasil Oftalmol"},{"key":"10.1016\/j.jcjo.2024.06.004_bib0010","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1001\/jamaophthalmol.2021.1275","article-title":"Comparison of central macular fluid volume with central subfield thickness in patients with diabetic macular edema using optical coherence tomography angiography","volume":"139","author":"You","year":"2021","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.jcjo.2024.06.004_bib0011","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.preteyeres.2013.02.001","article-title":"Molecular basis of the inner blood-retinal barrier and its breakdown in diabetic macular edema and other pathological conditions","volume":"34","author":"Klaassen","year":"2013","journal-title":"Prog Retin Eye Res"},{"key":"10.1016\/j.jcjo.2024.06.004_bib0012","doi-asserted-by":"crossref","first-page":"100","DOI":"10.2174\/1573399810666140402123026","article-title":"Laser treatment for diabetic macular edema in the 21st century","volume":"10","author":"Romero-Aroca","year":"2014","journal-title":"Curr Diab Rev"},{"key":"10.1016\/j.jcjo.2024.06.004_bib0013","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1007\/s11892-012-0281-8","article-title":"Corticosteroid use for diabetic macular edema: old fad or new trend?","volume":"12","author":"Stewart","year":"2012","journal-title":"Curr Diab Rep"},{"key":"10.1016\/j.jcjo.2024.06.004_bib0014","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2014\/632307","article-title":"Anti-VEGF for the management of diabetic macular edema","volume":"2014","author":"Stefanini","year":"2014","journal-title":"J Immunol Res"},{"key":"10.1016\/j.jcjo.2024.06.004_bib0015","first-page":"44","article-title":"Anti-VEGF drugs in the prevention of blindness","volume":"27","author":"Yortson","year":"2014","journal-title":"Commun Eye Health J"},{"key":"10.1016\/j.jcjo.2024.06.004_bib0016","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1177\/2042018813512360","article-title":"Anti-vascular endothelial growth factor therapy for diabetic macular edema","volume":"4","author":"Boyer","year":"2013","journal-title":"Ther Adv Endocrinol Metab"},{"key":"10.1016\/j.jcjo.2024.06.004_bib0017","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.ajo.2016.09.012","article-title":"Early and long-term responses to anti\u2013vascular endothelial growth factor therapy in diabetic macular edema: analysis of protocol I data","volume":"172","author":"Gonzalez","year":"2016","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.jcjo.2024.06.004_bib0018","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1016\/j.oret.2017.10.014","article-title":"Outcomes of diabetic macular edema eyes with limited early response in the VISTA and VIVID studies","volume":"2","author":"Pieramici","year":"2018","journal-title":"Ophthalmol Ret"},{"key":"10.1016\/j.jcjo.2024.06.004_bib0019","doi-asserted-by":"crossref","first-page":"210","DOI":"10.3928\/23258160-20200326-02","article-title":"Long-term vision outcomes in patients with DME and a limited early visual response to ranibizumab in RIDE and RISE","volume":"51","author":"Singh","year":"2020","journal-title":"Ophthalmic Surg Lasers Imaging Retina"},{"key":"10.1016\/j.jcjo.2024.06.004_bib0020","article-title":"Quantification of fluid compartment changes in patients with limited response to anti-VEGF treatment for diabetic macular edema using a machine learning algorithm in routine clinical practice","volume":"63","author":"Sastry","year":"2022","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.jcjo.2024.06.004_bib0021","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1016\/j.jfo.2019.10.018","article-title":"Efficacy and follow-up of anti-VEGF injections in diabetic macular edema in real-life practice at the Dijon University Medical Centre through the save sight registries","volume":"43","author":"Tessier","year":"2020","journal-title":"J Fr Ophtalmol"},{"key":"10.1016\/j.jcjo.2024.06.004_bib0022","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1001\/archophthalmol.2012.1107","article-title":"Factors associated with changes in visual acuity and central subfield thickness at 1 year after treatment for diabetic macular edema with ranibizumab","volume":"130","author":"Bressler","year":"2012","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.jcjo.2024.06.004_bib0023","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1001\/jamaophthalmol.2015.5346","article-title":"Persistent macular thickening after ranibizumab treatment for diabetic macular edema with vision impairment","volume":"134","author":"Bressler","year":"2016","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.jcjo.2024.06.004_bib0024","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1001\/jamaophthalmol.2017.6565","article-title":"Persistent macular thickening following intravitreous aflibercept, bevacizumab, or ranibizumab for central-involved diabetic macular edema with vision impairment","volume":"136","author":"Bressler","year":"2018","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.jcjo.2024.06.004_bib0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.ophtha.2015.08.015","article-title":"Association of baseline characteristics and early vision response with 2-year vision outcomes in the comparison of AMD treatments trials (CATT)","volume":"122","author":"Ying","year":"2015","journal-title":"Ophthalmology"},{"key":"10.1016\/j.jcjo.2024.06.004_bib0026","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1016\/j.ophtha.2013.02.034","article-title":"Long-term outcomes of ranibizumab therapy for diabetic macular edema: the 36-month results from two phase III trials","volume":"120","author":"Brown","year":"2013","journal-title":"Ophthalmology"},{"key":"10.1016\/j.jcjo.2024.06.004_bib0027","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.ajo.2018.07.030","article-title":"Early response to anti\u2013vascular endothelial growth factor and two-year outcomes among eyes with diabetic macular edema in protocol T","volume":"195","author":"Bressler","year":"2018","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.jcjo.2024.06.004_bib0028","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1016\/j.ophtha.2020.03.021","article-title":"Five-year outcomes after initial AFLIBERCEPT, bevacizumab, or ranibizumab treatment for diabetic macular edema (Protocol T extension study)","volume":"127","author":"Glassman","year":"2020","journal-title":"Ophthalmology"},{"key":"10.1016\/j.jcjo.2024.06.004_bib0029","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.ajo.2016.11.025","article-title":"Early and long-term responses to anti\u2013vascular endothelial growth factor therapy in diabetic macular edema: analysis of protocol I data","volume":"177","author":"Ophir","year":"2017","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.jcjo.2024.06.004_bib0030","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2018\/2353428","article-title":"Effects of smoking on outcomes of antivascular endothelial growth factor therapy in patients with neovascular age-related macular degeneration smoking and anti-VEGF therapy in NAMD","volume":"2018","author":"Kamao","year":"2018","journal-title":"J Ophthalmol"},{"key":"10.1016\/j.jcjo.2024.06.004_bib0031","article-title":"Smoking status and treatment outcomes of vascular endothelial growth factor inhibitors for neovascular age-related macular degeneration","volume":"40","author":"Vittorio","year":"2019","journal-title":"Retina"},{"key":"10.1016\/j.jcjo.2024.06.004_bib0032","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1111\/jdi.13801","article-title":"Treatment of diabetic macular edema in real-world clinical practice: the effect of aging","volume":"13","author":"Kusuhara","year":"2022","journal-title":"J Diabetes Invest"},{"key":"10.1016\/j.jcjo.2024.06.004_bib0033","doi-asserted-by":"crossref","first-page":"83","DOI":"10.3390\/life11020083","article-title":"Factors affecting a short-term response to anti-VEGF therapy in diabetic macular edema","volume":"11","author":"Usui-Ouchi","year":"2021","journal-title":"Life"}],"container-title":["Canadian Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0008418224001819?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0008418224001819?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,21]],"date-time":"2025-03-21T19:57:40Z","timestamp":1742587060000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0008418224001819"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":33,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["S0008418224001819"],"URL":"https:\/\/doi.org\/10.1016\/j.jcjo.2024.06.004","relation":{},"ISSN":["0008-4182"],"issn-type":[{"type":"print","value":"0008-4182"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Long-term visual outcomes and fluid compartment changes in limited-early versus early response to anti-VEGF treatment for diabetic macular edema","name":"articletitle","label":"Article Title"},{"value":"Canadian Journal of Ophthalmology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcjo.2024.06.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Published by Elsevier Inc. on behalf of Canadian Ophthalmological Society.","name":"copyright","label":"Copyright"}]}}